Details for Patent: 5,668,181

Title:	Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the treatment of depression
Abstract:	This invention relates to the use of R(+)-N-propargyl-1-aminoindan.
Inventor(s):	Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL)
Assignee:	Teva Pharmaceutical Industries Ltd. (Jerusalem, IL) Techion Research and Development Foundation Ltd. (Haifa, IL)
Filing Date:	Jun 02, 1995
Application Number:	08/458,645
Claims:	1. A method of treating a subject for depression, which comprises administering to the subject a pharmaceutical composition consisting essentially of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof in an amount effective to treat the subject and a carrier. 2. The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered orally or rectally. 3. The method of claim 2, wherein the amount administered is 2 to 20 mg per daily dosage unit. 4. The method of claim 3, wherein the amount administered is 5 to 10 mg per daily dosage unit. 5. The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered parenterally. 6. The method of claim 5, wherein the amount administered is 1 to 10 mg per mL per daily dosage unit. 7. The method of claim 6, wherein the amount administered is 2 to 5 mg per mL per daily dosage unit.